Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Oral Silybin-Phosphatidylcholine
NCT02633696Phase 1Completed
- Start
- Oct 2013
- Primary completion
- Nov 2013
- Modality
- Drug Delivery Systems, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of silybin + phosphatidylcholine in liver disease, Amanita phalloides poisoning and chronic liver disease (CLD) (2 arms). Primary endpoints: Maximum Plasma Concentration at 1 Month and Area Under the Curve at 1 Month. Started Oct 2013; status: completed.
02
Drugs
silybin + phosphatidylcholine
03
Conditions
liver diseaseAmanita phalloides poisoningchronic liver disease (CLD)
Beyond the preview
Go deeper on NCT02633696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633696.